Biotech Boom Thanks to Synergies: AstraZeneca Bets on Platforms, Almirall Forges Alliances, and Vidac Pharma Has the Multi-Tool

Almirall Focuses on Precision in Dermatology and Forges Alliances

The Spanish dermatology specialist Almirall demonstrates that European pharmaceutical companies, too, can hold their own among the international leaders. Rather than spreading itself too thin across countless projects, the Catalan company consistently focuses on inflammatory skin diseases and modern biologics. Recent financial results show this strategy is paying off. In fiscal year 2024, Almirall increased net revenue by 10.2% to EUR 985.7 million, generated operating EBITDA of EUR 192.6 million, and invested EUR 124.2 million, exactly 12.6% of revenue, in research and development. In the following year, revenue climbed further to EUR 1.11 billion, with a stable R&D ratio of 12.5%. The main revenue driver is the biologic Lebrikizumab, which neutralizes the inflammatory cytokine IL-13. Following regulatory approvals, the company is rolling out the antibody in key markets such as Germany, Austria, the United Kingdom, and Spain, while its licensing partner, Eli Lilly, handles overseas sales. At the same time, however, Almirall is facing margin pressure, as expanding distribution channels and costly Phase 3 regulatory extensions for young children tie up financial resources. To avoid falling behind the competition, the company is advancing its own pipeline candidates—such as the triple-signal-pathway inhibitor ALM27134, now in Phase 2—and is also securing market share in the treatment of actinic keratosis with tirbanibulin, though this requires funding field studies.

AstraZeneca Focuses on Major Platforms

Among the industry's major players, the British-Swedish conglomerate AstraZeneca demonstrates how cutting-edge translational research can be scaled up to an industrial level. With its long-term strategy, management aims to bring twenty novel drugs to market by the end of the current decade. As part of its roadmap, AstraZeneca is targeting annual revenue of USD 80 billion by 2030, having recently achieved revenue well over USD 50 billion. Crucial to these plans are massive research complexes such as the Discovery Centre in Cambridge, UK, and the campus in Gothenburg, Sweden. Nevertheless, AstraZeneca is also grappling with the typical challenges of modern cell therapies: autologous CAR-T procedures are extremely costly and time-consuming to produce, and they regularly fail to penetrate the dense protective barriers of solid tumors. To solve these problems, researchers are genetically engineering the body's own T cells to target the immunosuppressive cytokine TGF-beta or, through the acquired company Neogene Therapeutics, are using TCR-T constructs to attack intracellular targets. At the same time, AstraZeneca is advancing cellular CAR-T platforms for complex autoimmune diseases such as lupus erythematosus. These innovative therapies require significant capital and complex logistics.

Vidac Pharma Reverses the Metabolism of Cancer Cells

While industry giants are investing billions in existing platforms, the biotech company Vidac Pharma is taking a more radical approach. The research team is tackling a phenomenon that has fascinated experts since the days of German researcher and Nobel laureate Otto Warburg—cancer cells behave like parasites in the body. They completely switch their metabolic engine and burn vast amounts of sugar to grow faster. Normally, a kind of "biological emergency brake" ensures that severely damaged cells die on their own. In tumors, however, a specific enzyme bypasses this protective mechanism. The enzyme migrates to the cell's powerhouses, docks there at a tiny gate, and directly diverts energy. At the same time, it locks this gate shut like a wedge. As a result, the body's own signals for programmed cell death can no longer get through, and the cancer cell becomes virtually immortal.

This is exactly where Vidac Pharma's active ingredient comes into play: it acts like a precise molecular lockpick. The molecule breaks the bond between the enzyme and the cellular gate. As soon as the enzyme is pushed aside, the tumor's uncontrolled sugar rush collapses. The gate reopens, the cell receives its natural self-destruction signals, and dies in a controlled manner. Because healthy body cells use different molecular building blocks and do not block these gates in the first place, the therapy targets only the diseased tissue. In a controlled Phase 2a clinical trial, the topical ointment VDA-1102 reduced the number of skin lesions in high-risk patients with actinic keratosis, a precursor to non-melanoma skin cancer, by a median of 64.6% compared to a placebo. Crucially for patients: the agonizing, inflammatory skin damage associated with common standard therapies was completely absent. The European follow-up study to validate the data is already underway, after the Wuppertal-based study centre Centroderm began the treatment in February 2026 and completed recruitment of all 39 participants in June 2026.

Pipeline Potential and Promising Alliances at Vidac Pharma

The range of applications for Vidac Pharma's drug platform by no means ends with skin cancer or its precursor lesions. The drug VDA-1275 offers the most exciting potential for future partnerships. This novel chemical compound is currently undergoing preclinical testing against colorectal, lung, and liver tumors. Laboratory findings show that the compound transforms tumor-promoting M2 macrophages into cytotoxic M1 cells and stimulates the formation of protective CD8 memory cells. Furthermore, in three-dimensional organoid models of human liver tumors, the compound drastically reduced the required dosage of established cytostatic drugs such as cisplatin. Given such synergies, Vidac Pharma is an exciting company that could partner with many larger biotech firms or pharmaceutical conglomerates. Almirall could serve as a model; with its EUR 300 million mRNA partnership with Etherna and its AI agreement with Absci worth up to USD 650 million, Almirall has demonstrated how even a mid-sized company can make a big splash by collaborating with partners.